Method of treating stress hyperglycemia with human antibodies to the glucagon receptor

Patent metadata

Field	Value
Publication number	US-9358287-B2
Application number	US-201414286606-A
Country	US
Kind code	B2
Filing date	May 23, 2014
Priority date	Nov 23, 2010
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.

First claim

What is claimed is:

1. A method of reducing the amount and/or dosage of insulin necessary to lower blood glucose levels to a normal range in a patient at risk for developing stress hyperglycemia, or in a patient suffering from stress hyperglycemia, the method comprising administering, concomitantly with insulin, an effective amount of a glucagon receptor (GCGR) antagonist, wherein the GCGR antagonist is an isolated human monoclonal antibody that binds specifically to the glucagon receptor.

2. The method of claim 1 , wherein the amount and/or dosage of insulin may be reduced by about 30% to about 95% when administered concomitantly with a GCGR antagonist, wherein the antagonist is an isolated human monoclonal antibody that binds specifically to the glucagon receptor.

3. The method of claim 2 , wherein the amount and/or dosage of insulin may be reduced by about 90% when administered concomitantly with a GCGR antagonist, wherein the antagonist is an isolated human monoclonal antibody that binds specifically to the glucagon receptor.

4. The method of claim 1 , wherein the GCGR antagonist is an isolated human monoclonal antibody comprising the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR), wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 70, 86, 90, 106, 110, 126, 130 and 146; and the CDRs of a light chain variable region (LCVR), wherein the LCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 68, 78, 88, 98, 108, 118, 128, 138 and 148.

5. The method of claim 4 , wherein the isolated human monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 70, 86, 90, 106, 110, 126, 130 and 146.

6. The method of claim 4 , wherein the isolated human monoclonal antibody or antigen-binding fragment thereof comprises a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 68, 78, 88, 98, 108, 118, 128, 138 and 148.

7. The method of claim 4 , wherein the isolated human monoclonal antibody or antigen-binding fragment thereof comprises: (a) a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 70, 86, 90, 106, 110, 126, 130 and 146; and (b) a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 68, 78, 88, 98, 108, 118, 128, 138 and 148.

8. The method of claim 4 , wherein the isolated human monoclonal antibody or antigen-binding fragment thereof comprises:
(a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 72, 92, 112 and 132;
(b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 22, 38, 54, 74, 94, 114 and 134;
(c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 76, 96, 116 and 136;
(d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 28, 44, 60, 80, 100, 120 and 140;
(e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 14, 30, 46, 62, 82, 102, 122 and 142; and
(f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 16, 32, 48, 64, 84, 104, 124 and 144.

9. The method of claim 4 , wherein the isolated human monoclonal antibody or antigen-binding fragment comprises a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NO: 2/10, 18/26, 34/42, 50/58, 66/68, 70/78, 86/88, 90/98, 106/108, 110/118, 126/128, 130/138, and 146/148.

10. The method of claim 4 , wherein the isolated human monoclonal antibody comprises a HCVR/LCVR amino acid sequence pair as set forth in SEQ ID NOs: 86/88.

Assignees

• Regeneron Pharma

Inventors

• Harp Joyce
• Okamoto Haruka

Classifications

• A61K39/39541

  against normal tissues, cells · CPC title

• C07K16/2869 Primary

  against hormone receptors (for antibodies against neuromediator receptors C07K16/286) · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title